EIKN (NASDAQ:EIKN) Receives Average Rating of “Moderate Buy” from Brokerages

EIKN (NASDAQ:EIKN) has earned an average rating of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $25.20.

Several research analysts have commented on EIKN shares. JPMorgan Chase & Co. started coverage on shares of EIKN in a research note on Monday, March 2nd. They set an “overweight” rating and a $29.00 price target on the stock. Wall Street Zen downgraded shares of EIKN from a “hold” rating to a “sell” rating in a research note on Sunday, April 5th. Wedbush dropped their target price on EIKN from $7.00 to $5.00 and set an “underperform” rating for the company in a report on Tuesday. Morgan Stanley assumed coverage on EIKN in a report on Monday, March 2nd. They set an “overweight” rating and a $32.00 target price for the company. Finally, Bank of America assumed coverage on EIKN in a research note on Monday, March 2nd. They issued a “buy” rating and a $34.00 price target on the stock.

EIKN Trading Up 0.5%

EIKN stock opened at $13.25 on Friday. EIKN has a one year low of $7.90 and a one year high of $17.40. The business’s 50 day simple moving average is $10.98.

EIKN (NASDAQ:EIKN) last posted its quarterly earnings results on Monday, March 30th. The company reported ($26.23) EPS for the quarter.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.